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The development of radiotracers for use in vivo to image β-amyloid (Aβ) plaques in cases of Alzheimer’s disease (AD) is an
important, active area of research. The presence of Aβ aggregates in the brain is generally accepted as a hallmark of AD. Since the
only deﬁnitive diagnosis of AD is by postmortem staining of aﬀected brain tissue, the development of techniques which enable one
to image Aβ plaques in vivo has been strongly desired. Furthermore, the quantitative evaluation of Aβ plaques in the brain could
facilitate evaluation of the eﬃcacy of antiamyloid therapies currently under development. This paper reviews the current situation
in the development of agents for SPECT-based imaging of Aβ plaques in Alzheimer’s brains.
1.Introduction
Alzheimer’s disease (AD) is an age-related, irreversible form
of dementia characterized by memory loss, a progressive
decline in intellectual ability, language impairment, and per-
sonalityandbehavioralchangesthateventuallyinterferewith
daily life. The accumulation of β-amyloid (Aβ)a g g r e g a t e s
(major protein aggregates of senile plaques) in the brain is
considered one of the hallmarks of AD [1, 2]. Today, the
clinical diagnosis of AD is primarily based on history and
memory testing, which is often diﬃcult and not accurate,
as the early cognitive and behavioral symptoms of AD
are diﬃcult to distinguish from normal signs of aging. To
facilitate the early diagnosis of this disease, there is an urgent
need for the sensitive noninvasive detection of biomarkers
for the pathophysiology. Toward achieving this goal, nuclear
imaging techniques such as positron emission computed
tomography (PET) and single photon emission computed
tomography (SPECT) have been employed. Radionuclide-
labeled agents targeting the Aβ plaques in the brain may
greatly facilitate the diagnosis of AD and new antiamy-
loid therapies [3–7]. The diﬀerential diagnosis for AD
includes a large number of other diseases such as vascular
dementia, frontal temporal lobe dementia (FTLD) complex,
and dementia with Lewy bodies (DLB) as well as rarer
neurodegenerative diseases such as Creutzfeld-Jacob disease
(CJD).Importantly,ADsubjectswillalwayshaveAβ plaques,
whereas Aβ is seen not at all or only sporadically in most of
these other diseases. In each case, appropriate prognosis and
treatment require accurate diagnostic assessment.
Developing Aβ imaging agents is currently an emerging
ﬁeld of research. The basic requirements for suitable Aβ
imaging agents include (i) good penetration of the blood-
brain barrier, (ii) selective binding to Aβ plaques, and
(iii) clear and contrasting signals between plaques and
nonplaques (Figure 1). Based on these requirements, several
promising agents with the backbone structure of DDNP,
thioﬂavin-T and Congo Red have been synthesized and
evaluated for use in vivo as probes to image Aβ plaques in
AD brain. Clinical trials in AD patients have been conducted
with several PET imaging agents including [11C]PIB [8–10],
[11C]SB-13 [6, 11], [11C]BF-227 [12], [11C]AZD2184 [13],
[18F]FDDNP [14–16], [18F]BAY94-9172 [7, 17, 18], [18F]
AV-45 [19–21], and [18F]GE-067 [22]( Figure 2), indicating
the imaging of Aβ plaques in living brain tissue to be useful
for the diagnosis of AD. The 11C-labeled agents limit their
use to on-site cyclotrons and sophisticated radiochemistry
laboratories due to the short half-life (20min) of 11C.
PET agents with the longer half-life (110min) radioisotope
18F have recently been developed and could increase the
availability of Aβ imaging to all PET facilities, but still
represents a minority of modern hospitals, as only a small
fraction of hospitals have a PET scanner. Since SPECT is
more valuable than PET in terms of routine diagnostic2 International Journal of Molecular Imaging
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Figure 1: Strategy of in vivo imaging of cerebral Aβ plaques.
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Figure 2: Chemical structure of PET imaging agents tested clinically.
use, the development of more useful Aβ imaging agents
for SPECT has been a critical issue. However, progress
in developing imaging agents targeting Aβ plaques is less
advanced for SPECT than PET. In this review, we summarize
the current situation in the development of probes for
SPECT-based imaging of Aβ plaques in Alzheimer’s brains.
2. RadioiodinatedProbesfor
Imaging of Aβ Plaques
Many radioiodinated imaging agents derived from Congo
Red or thioﬂavin-T have been developed. Compounds 1
[29], 2 [29], 3 [40], 4 [23], 5 [24], and 6 [25]( Figure 3)a r e
thought to be derived from Congo Red. Although 1, 2,a n d
3 showed unfavorable pharmacokinetics in vivo such as low
uptake into the brain and a slow washout, the radioactivity
pharmacokinetics of 5 and 6 was much improved. Because
thioﬂavin-T has a lower molecular weight than Congo
Red, implying greater blood-brain penetration, a number of
groups have worked to develop probes for SPECT derived
from thioﬂavin-T including 7 (IMPY) [26–28], 8 (TZDM)
[29], 9 (IBOX) [30], 10 (benzofuran derivatives) [31], and
11 (phenylindole derivatives) (Figure 4)[ 32].
Initially, Zhuang and coworkers prepared iodo-
strylbenzene derivatives based on the chemical structure
of Congo Red, [125I]IMSB (1)a n d[ 125I]ISB (2). These
ligands exhibited low brain uptake likely due to two
ionizable carboxyl groups [29]. Thus, a small and neutral
thioﬂavin-T analog, [125I]TZDM (8), was prepared [29]. In
vitro binding studies of these ligands, [125I]ISB, [125I]IMSB
and [125I]TZDM, showed excellent binding aﬃnities with
Kd values of 0.08, 0.13 and 0.06nM for aggregates of
Aβ(1–40) and 0.15, 0.73 and 0.14nM for aggregates of
Aβ(1–42), respectively. Interestingly, in a competitive-
binding assay, diﬀerent binding sites on Aβ(1–40) and
Aβ(1–42) aggregates, which are mutually exclusive, were
observed for Congo Red and thioﬂavin-T derivatives.
Biodistribution experiments in normal mice after an i.v.
injection showed that [125I]TZDM exhibited good uptake
and retention in the brain, much higher than [125I]ISB and
[125I]IMSB. Preliminary experiments on the biodistribution
of [125I]TZDM in transgenic mice, engineered to produce
excess Aβ plaques in the brain as an AD model, suggested
labeling of Aβ aggregates in vivo.H o w e v e r ,[ 125I]TZDM is
not ideal as an imaging agent in vivo, due to its labeling of
white matter, which signiﬁcantly increases the backgroundInternational Journal of Molecular Imaging 3
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Figure 5: Chemical structure of SPECT imaging agents based on
ﬂavone (12–15), chalcone (16), and aurone (17).
activity. To improve the pharmacokinetics of uptake and
retention, Kung et al. and others have prepared several
compounds derived from thioﬂavin-T and studied features
such as aﬃnity for Aβ aggregates in vitro and biodistribution
in vivo. Interestingly, the compounds with good binding to
Aβ aggregates share a common structural feature: either an
N-methylamino- or N,N-dimethylaminophenyl group at
one end of the molecule. The structural feature required for
binding to Aβ aggregates appears to be simple and unique.
[123I]IMPY has been characterized as a potential agent
for SPECT-based imaging of Aβ plaques. IMPY displayed
selective labeling of Aβ plaques ex vivo in autoradiographic
experiments using double-transgenic mice (PSAPP) as a
m o d e lo fA D[ 33]. Preliminary clinical data on [125I]IMPY
in normal and AD patients showed a distinct distribution
pattern similar to that of [11C]PIB [34, 35]. However, the
signal-to-noise ratio for plaque labeling is not as high as
that of [11C]PIB. The low contrast may be due to the fast
clearance from brain and plasma observed in AD and
normal subjects. But the rapid metabolism and instability
of [123I]IMPY in vivo may have led to less than optimal
signal-to-noise ratios for targeting Aβ plaques in the brain.
Additional candidates are being explored for SPECT imaging
of Aβ plaques in the brain.
Recently, the eﬀects of polyhydroxyﬂavones on the
formation, extension, and destabilization of Aβ aggregates
have been studied in vitro [36]. These ﬂavones dose-
dependentlyinhibitedtheformationofAβaggregates,aswell
as destabilized preformed Aβ aggregates, indicating that they
could interact directly with the aggregates. The ﬁndings in
t h a tr e p o r tp r o m p t e du st ou s eﬂ a v o n e sa sac o r es t r u c t u r e
in the development of Aβ imaging agents. Furthermore,
some recent studies have shown that electron-donating
groups such as methylamino, dimethylamino, methoxy, and
hydroxy groups play a critical role in the binding to Aβ
aggregates. With these considerations in mind, we designed4 International Journal of Molecular Imaging
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Figure 6: Scatchard plots of the binding of [125I]12 to aggregates of Aβ(1–40) (a) and Aβ(1–42) (b).
four radioiodinated ﬂavones with a radioiodine at the 6-
position and an electron-donating group at the 4 -position
(Figure 5).Thenwesynthesizedaseriesofﬂavonederivatives
and evaluated their usefulness in vivo as SPECT Aβ imaging
agents [37].
Experiments on the binding of [125I]12 to aggregates of
Aβ(1–40) and Aβ(1–42) were carried out. Transformation
of the saturation binding of [125I]12 to Scatchard plots gave
linear plots, suggesting one binding site (Figure 6). [125I]12
showed excellent aﬃnity for both Aβ(1–40) (Kd = 12.4 ±
2.3nM)andAβ(1–42) (Kd = 17.4±5.7nM) aggregates. The
binding of nonradioactive ﬂavone derivatives (compounds
12, 13, 14,a n d15) was evaluated in experiments inhibiting
[125I]12 from binding Aβ(1–40) and Aβ(1–42) aggregates.
As shown in Table 1,a l lﬂ a v o n ed e r i v a t i v e sc o m p e t e dw e l l
with [125I]12 (Ki = 13–77nM). More interestingly, when
thioﬂavin-T, and Congo Red gave high Ki values (>1000nM)
(Table 1), indicating little competition. This ﬁnding suggests
that these ﬂavones may have a binding site on Aβ aggregates
diﬀerent from that of thioﬂavin T and Congo Red, although
additional studies regarding the selectivity of binding aﬃnity
for Aβ aggregates are required.
Since the in vitro binding assays demonstrated the high
aﬃnity of the ﬂavone derivatives for Aβ(1–40) and Aβ(1–42)
aggregates, compounds 12, 13, 14,a n d15 were investigated
for their neuropathologic staining of Aβ plaques and NFTs
in human AD brain sections (Figure 7). The compounds
intensely stained Aβ plaques (Figures 7(a), 7(e), 7(i), and
7(m)), neuritic plaques (Figures 7(b), 7(f), 7(j), and 7(n)),
and cerebrovascular amyloids (Figures 7(c), 7(g), 7(k), and
7(o)) with nearly the same pattern. However, as seen in
Table 1: Inhibition constants (Ki,n M ) a of compounds for the
binding of ligands to aggregates of Aβ(1–40) and Aβ(1–42).
Compound Aβ(1–40) Aβ(1–42)
12 22.6 ± 3.4 30.0 ± 3.4
13 13.2 ± 0.2 15.6 ± 2.4
14 29.0 ± 3.2 38.3 ± 8.1
15 72.5 ± 8.2 77.2 ± 9.2
Thioﬂavin T >1000 >1000
Congo Red >1000 >1000
aValues are the mean ± standard error of the mean for 6 independent
experiments.
Figures 7(a), 7(e), 7(i), and 7(m), these ﬂavone compounds
did not intensely stain the core region in so-called classic Aβ
plaques, unlike the thioﬂavin-T and Congo Red derivatives
previously reported as Aβ imaging probes, indicating that
ﬂavone derivatives may have somewhat distinct binding
characteristics for amyloid ﬁbrils. These ﬂavone derivatives
appear to stain not only neuritic Aβ plaques but also diﬀuse
amyloid plaque deposits, which are known to be mainly
composed of Aβ(1−42) [38] and to be the initial pathologic
change in AD [39]. Thus ﬂavone derivatives with high
aﬃnity for Aβ(1–42)-positive diﬀuse plaques may be more
usefulforpresymptomaticdetectionofAD.Furthermore,12,
13,14,a n d15 also showed high aﬃnity for NFTs in AD brain
sections (Figures 7(d), 7(h), 7(l), and 7(p)). These ﬁndings
suggest that these ﬂavone derivatives can bind amyloid ﬁbrils
and NFTs without the backbone structure of thioﬂavin-T or
Congo Red and that quantitative evaluation of their cerebralInternational Journal of Molecular Imaging 5
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Figure 7: Neuropathological staining of compounds 12 (a)–(d), 13 (e)–(h), 14 (i)–(l), and 15 (m)–(p) on 5μm AD brain sections from
the temporal cortex. (a) Aβ plaques (a), (e), (i), and (m) are clearly stained with 12, 13, 14, and 15 (×40 magniﬁcation). Clear staining of
neuritic plaques (b), (f), (j), and (n) and cerebrovascular amyloid (c), (g), (k), and (o) was also obtained. Many NFTs (d), (h), (l), and (p)
are intensely stained with 12, 13, 14,a n d15 (×40 magniﬁcation).
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localization may provide useful information on Aβ and tau
pathology.
Four radioiodinated ﬂavone ligands ([125I]12,[ 125I]13,
[125I]14, and [125I]15) were evaluated for their biodistribu-
tion in vivo in normal mice. Previous studies suggest that
the optimal lipophilicity range for brain entry is observed
for compounds with log P-v a l u e sb e t w e e n1a n d3[ 5]. All
four ligands displayed optimal lipophilicity as reﬂected by
log P-values of 1.94, 2.69, 2.41, and 1.92, respectively. As
expected, these ligands exhibited high uptake ranging from
3.2% to 4.1% ID/g brain at 2min postinjection, a level
suﬃcient for imaging in the brain (Table 2). In addition,
they displayed good clearance from the normal brain:
1.2, 1.0, 0.17, and 0.08% ID/g at 60min postinjection
for [125I]12,[ 125I]13,[ 125I]14,a n d[ 125I]15,r e s p e c t i v e l y .
Radioiodinated amyloid imaging agents such as [125I]m-
I-stilbene (3)[ 40], [125I]TZDM (8)[ 29], [125I]IBOX (9)
[30], and [125I]benzofuran (10)[ 31], and [125I]phenylindole
(11)[ 32] reported previously showed good uptake, but
a relatively slow washout from the normal brain. A low
washout rate leads to high background activity and prevents
the visualization of Aβ plaques in the AD brain. Appropriate
properties in vivo (higher uptake and faster washout from
the normal brain) make radioiodinated ﬂavones useful
candidates for SPECT tracers for Aβ imaging.
On the basis of this success in the development of SPECT
imaging agents, to search for more useful candidates for Aβ
imagingprobes,wehavedesignedachemicalmodiﬁcationof
the ﬂavone structure, and selected the chalcone and aurone
structure as a novel core for Aβ imaging probes (Figure 5)
[41, 42]. Chalcone and aurone are categorized as ﬂavonoids
containing a ﬂavone. We newly designed and synthesized
novel chalcone and aurone derivatives, and evaluated the6 International Journal of Molecular Imaging
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eﬀect of their structure–activity relationships on binding to
Aβ aggregates and biodistribution in vivo using a compound
with high aﬃnity [42–45]. Currently, SPECT imaging agents
based on chalcone and aurone are optimized.
Most of the Aβ imaging probes reported previously
have two aromatic rings. Among them, 1,4-diphenyltriazole
and 2,5-diphenylthiophene derivatives have triazole and
thiophenebetweentwobenzenerings,respectively,andithas
been shown that they have high-binding aﬃnity for binding
to Aβ aggregates despite the kinds of substituted groups
[46, 47]. In an attempt to further develop novel ligands for
the imaging of Aβ plaques in AD, we designed a series of 3,5-
diphenyl-1,2,4-oxadiazole (18)[ 48, 49] and 2,4-diphenyl-
1,3,5-oxadiazole (19)[ 49] derivatives (Figure 8). AlthoughInternational Journal of Molecular Imaging 7
Table 2: Biodistribution of radioactivity after intravenous injection of [125I]12,[ 125I]13,[ 125I]14, and [125I] 15 in normal micea
.
Tissue Time after injection (min)
2 1 03 06 0
[125I]12
Blood 1.89 (0.28) 1.39 (0.10) 1.34 (0.07) 1.50 (0.09)
Liver 16.28 (0.90) 25.28 (0.31) 18.61 (1.81) 15.14 (0.89)
Kidney 8.13 (1.28) 5.21 (0.44) 3.85 (0.33) 3.05 (0.25)
Intestine 3.10 (0.61) 7.91 (1.05) 12.84 (1.18) 21.48 (3.17)
Spleen 2.57 (1.54) 2.31 (0.01) 1.76 (0.23) 1.52 (0.29)
Heart 4.87 (0.66) 2.66 (0.12) 1.67 (0.14) 1.28 (0.12)
Stomachb 0.78 (0.02) 0.87 (0.22) 1.44 (0.69) 1.80 (0.84)
Brain 4.12 (0.15) 3.68 (0.18) 1.84 (0.12) 1.19 (0.04)
[125I]13
Blood 1.87 (0.18) 1.07 (0.08) 1.20 (0.15) 1.15 (0.16)
Liver 15.41 (0.98) 21.85 (2.14) 15.71 (0.96) 12.40 (2.38)
Kidney 8.33 (1.47) 4.31 (0.28) 3.40 (0.31) 2.32 (0.45)
Intestine 2.24 (0.24) 6.56 (0.83) 12.97 (1.15) 18.64 (2.05)
Spleen 2.72 (0.20) 1.92 (0.33) 1.58 (0.31) 1.18 (0.17)
Heart 5.63 (0.80) 2.47 (0.14) 1.69 (0.06) 1.07 (0.17)
Stomachb 0.73 (0.17) 0.63 (0.16) 1.17 (0.40) 1.06 (0.27)
Brain 3.22 (0.15) 3.61 (0.60) 1.89 (0.21) 0.99 (0.10)
[125I]14
Blood 1.87 (0.21) 1.19 (0.17) 0.40 (0.01) 0.23 (0.09)
Liver 8.96 (1.48) 9.01 (0.97) 3.75 (0.47) 1.88 (0.61)
Kidney 7.99 (1.08) 6.30 (1.02) 4.51 (1.59) 1.46 (1.12)
Intestine 3.52 (0.29) 14.39 (0.80) 22.51 (1.11) 30.05 (3.61)
Spleen 2.70 (0.08) 1.38 (0.37) 0.55 (0.30) 3.67 (5.89)
Heart 4.98 (0.41) 2.25 (0.40) 0.84 (0.14) 0.47 (0.22)
Stomachb 0.68 (0.06) 0.45 (0.18) 0.55 (0.33) 0.31 (0.07)
Brain 4.00 (0.18) 2.36 (0.33) 0.51 (0.07) 0.17 (0.05)
[125I]15
Blood 2.77 (0.43) 1.58 (0.18) 0.66 (0.03) 0.20 (0.02)
Liver 9.77 (1.89) 8.24 (0.50) 6.80 (0.86) 4.78 (1.09)
Kidney 14.79 (2.59) 15.11 (2.00) 6.45 (0.84) 1.66 (0.62)
Intestine 3.12 (0.37) 11.26 (0.63) 22.01 (1.34) 27.28 (0.48)
Spleen 3.92 (1.18) 1.55 (0.15) 0.56 (0.13) 0.17 (0.06)
Heart 5.51 (0.71) 1.60 (0.18) 0.53 (0.04) 0.12 (0.02)
Stomachb 0.89 (0.09) 0.59 (0.16) 1.56 (0.50) 0.81 (0.36)
Brain 3.31 (0.32) 1.90 (0.07) 0.52 (0.03) 0.08 (0.02)
aExpressed as % injected dose per gram. Each value represents the mean ± S.D. for 3−5 animals at each interval. bExpressed as % injected dose per organ.
the diphenyloxadiazole pharmacophore with high-binding
aﬃnity for Aβ aggregates may be useful as a backbone
structure to develop novel Aβ imaging agents, additional
modiﬁcations are necessary to improve the uptake and rapid
clearance of nonspeciﬁcally bound radiotracers.
Many factors such as molecular size, ionic charge,
and lipophilicity aﬀect the brain uptake of compounds.
Since lipophilicity of the compounds generally increases by
introduction of iodine, the large higher lipophilicity of the
radioiodinatedcompoundsmayconstituteonereasonforthe
low brain uptake. In the future, introduction of hydrophilic
substituted groups into the amyloid-binding scaﬀolds will be
required to develop more promising radioiodinated tracers
with in favorable in vivo pharmacokinetics.
3. 99mTc Complexes for Imaging of Aβ Plaques
99mTc (T1/2 = 6.01h, 141keV) has become the most
commonly used radionuclide in diagnostics for SPECT,
because it is readily produced by an 99Mo/99mTc generator,
the medium gamma-ray energy it emits is suitable for
detection, and its physical half-life is compatible with the
biological localization and residence time required for imag-
ing. Its ready availability, essentially 24h a day, and easiness8 International Journal of Molecular Imaging
Table 3: Biodistribution of radioactivity after injection of 99mTc-labeled benzofuran derivatives in normal micea.
Organ Time after injection (min)
21 03 06 0
99mTc-BAT-BF (27)
Blood 4.40 (0.27) 1.96 (0.06) 1.93 (0.26) 2.15 (0.91)
Liver 21.94 (5.94) 20.87 (1.28) 19.65 (1.31) 15.09 (3.83)
Kidney 10.28 (1.76) 7.90 (0.40) 4.27 (0.18) 2.70 (0.57)
Intestineb 1.45 (0.18) 3.68 (0.52) 7.42 (1.62) 9.02 (1.93)
Spleen 5.20 (1.01) 3.09 (0.23) 1.69 (0.21) 1.16 (0.14)
Lung 26.70 (2.27) 6.48 (1.33) 3.51 (0.64) 2.36 (0.48)
Stomachb 1.33 (0.57) 1.90 (0.43) 4.09 (1.37) 4.17 (1.92)
Pancreas 4.14 (0.77) 4.57 (0.24) 2.98 (0.38) 1.42 (0.15)
Heart 17.60 (2.60) 8.29 (0.97) 3.28 (1.35) 1.51 (0.25)
Brain 1.34 (0.12) 1.37 (0.18) 0.94 (0.20) 0.56 (0.07)
99mTc-MAMA-BF (28)
Blood 4.13 (0.42) 1.78 (0.25) 2.15 (0.12) 2.24 (0.24)
Liver 20.17 (3.81) 21.62 (2.62) 23.32 (1.59) 20.16 (2.13)
Kidney 7.37 (1.06) 8.09 (1.16) 5.11 (0.29) 3.28 (0.45)
Intestineb 0.95 (0.22) 2.13 (0.19) 4.75 (0.93) 5.73 (0.66)
Spleen 4.48 (0.56) 3.69 (0.34) 3.49 (0.61) 2.59 (0.65)
Lung 24.04 (5.17) 7.59 (2.13) 4.24 (0.35) 3.54 (1.26)
Stomachb 0.73 (0.21) 2.35 (0.58) 4.94 (0.57) 2.81 (0.51)
Pancreas 2.70 (0.47) 4.00 (1.28) 5.48 (0.61) 3.76 (0.36)
Heart 12.28 (2.20) 10.48 (1.79) 5.05 (0.90) 2.16 (0.34)
Brain 0.74 (0.15) 0.99 (0.22) 1.23 (0.09) 0.89 (0.08)
aEach value represents the mean (SD) for 5 mice. Expressed as % injected dose per gram. bExpressed as % injected dose per organ.
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Figure 11: Chemical structure of 99mTc complexes based on the
benzofuran scaﬀold for imaging of Aβ plaques.
of use make it the radionuclide of choice. New 99mTc-
labeled imaging agents will provide simple, convenient,
and widespread SPECT-based methods for detecting and
eventually quantifying Aβ plaques in living brain tissue.
Han and co-workers described a positively charged 99Tc-
complex of Congo red (20) which binds to Aβ aggregates in
vitro [50]. The basic structure of this complex is the Congo
red backbone in which the biphenyl moiety is replaced
by a bipyridyl moiety capable of complexing Tc in the
presence of tert-butylisonitrile as a coligand. Although these
Tc complexes showed high aﬃnity for Aβ aggregates in vitro,
they have not been tested in vivo.D e z u t t e ra n dc o - w o r k e r s
reported a 99mTc-labeled conjugate of Congo Red with a
monoamide-monoaminedithiol (MAMA) chelating ligand
[51].However,brainuptakeofthis 99mTc-labeledCongoRed
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Figure 12: Inhibition curves of Re-BAT-BF and Re-MAMA-BF for
the binding of [125I]IMPY to Aβ(1–42) aggregates.
derivative (21) was minimal, probably because of its large
size and ionized character at physiological pH. Serdons and
co-workers reported the synthesis of a neutral 99mTc-labeled
derivative of thioﬂavin-T (22), namely a benzothiazole
derivative conjugated with a bisamine-bisthiol (BAT) ligand,
and its biological characterization [52]. It was demonstratedInternational Journal of Molecular Imaging 9
(a) (b)
Figure 13:Autoradiographyof 99mTc-BAT-BF(27)insectionsfromTg2576mousebrain(a).Labeledplaqueswereconﬁrmedbythestaining
of the adjacent sections with thioﬂavin S (b).
that the 99mTc-labeled thioﬂavin-T derivative binds in vitro
to Aβ plaques. Despite its high lipophilicity and neutral
character, the 99mTc complex did not cross the blood-brain
barrier to a suﬃcient degree and thus is not useful for the
detection of AD in vivo. Recently, Chen et al. reported that
the 99mTc-labeled thioﬂavin T using MAMA as a chelation
ligand (23) demonstrated the binding to Aβ aggregates
in sections of brain tissue from transgenic mice and AD
patients [53]. In addition, 23 can penetrate the blood-brain
barrier with high initial brain uptake and moderate washout.
These results are encouraging for further exploration of their
derivatives as imaging agents for Aβ plaques in the brain.
Asdescribedabove,several 99mTc-labeledimagingprobes
have been developed (Figure 9)[50–55],butnoclinicalstudy
of them has been reported. While these 99mTc complexes
showed high aﬃnity for Aβ aggregates or Aβ plaques in vitro,
they suﬀered the same unfavorable in vivo pharmacokinetics
in normal mice, that is, a slow washout. Therefore, to
make them promising probes for imaging Aβ plaques in the
brain, additional molecular modiﬁcations to improve their
pharmacokinetics in vivo are required.
R e c e n t l y ,w eh a v ed e v e l o p e ds e v e r a l99mTc complexes
based on ﬂavone, chalcone, aurone, and benzofuran deriva-
tives with monoamine-monoamide dithiol (MAMA) and
bis-amino-bis-thiol (BAT) as chelation ligands (Figures
10 and 11). MAMA and BAT were selected taking into
consideration the permeability of the blood-brain barrier,
because they form an electrically neutral complex with 99mTc
[56]. We then evaluated their biological potential as probes
by testing their aﬃnity for Aβ aggregates and Aβ plaques in
sectionsofbraintissuefromTg2576miceandtheiruptakein
and clearance from the brain in biodistribution experiments
using normal mice.
Initially, four 99mTc-labeled chalcone derivatives and
theircorrespondingrheniumanaloguesweretestedaspoten-
tial probes for imaging Aβ plaques (Figure 10)[ 57]. The
chalcones showed higher aﬃnity for Aβ(1–42) aggregates
than did 99mTc complexes and, in sections of brain tissue
from an animal model of AD, the four Re-chalcones
intensely stained Aβ plaques. In biodistribution experiments
using normal mice, 99mTc-BAT-chalcone (24) displayed high
uptake in the brain (1.48%ID/g) at 2min after injection. The
radioactivity washed out from the brain rapidly (0.17%ID/g
at 60min), a highly desirable feature for an imaging agent.
Although potential existence of cis-a n danti-isomers was
expected, one single isomer was isolated in the preparation
of 24, 25, and 26. The chemical identities of 24, 25, and
26 were conﬁrmed by NMR and MS, but their absolute
conﬁgurations have not yet been determined by X-ray
crystallography.
As for 99mTc complexes based on benzofuran, we eval-
uated binding aﬃnity using Re-BAT-BF and Re-MAMA-
BF, analogs of 99mTc-BAT-BF (27)a n d99mTc-MAMA-BF
(28), respectively. Both ligands inhibited the binding of
[125I]IMPY to Aβ(1–42) aggregates in a dose-dependent
manner, indicating an aﬃnity for Aβ aggregates (Figure 12).
Their Ki values were 11.5 and 24.4nM, respectively, sug-
gesting that Re-BAT-BF displayed higher aﬃnity than Re-
MAMA-BF. Next, the aﬃnity of 99mTc-BAT-BF (27)f o rA β
plaques was investigated in vitro using sections of Tg2576
mouse brain (Figure 13). Furthermore, the radioactivity of
99mTc-BAT-BF (27) corresponded with the areas of staining
with thioﬂavin S, a dye commonly used for Aβ plaques.
In contrast, normal mouse brain displayed no detectable
accumulationof 99mTc-BAT-BF(27).Theresultssuggestthat
99mTc-BAT-BF (27) binds to Aβ plaques in the mouse brain
in addition to synthetic Aβ aggregates.
The biodistribution of 99mTc-BAT-BF (27)a n d99mTc-
MAMA-BF (28) was examined in normal mice (Table 3).
99mTc-BAT-BF (27) showed greater uptake (1.34%ID/g)
than 99mTc-MAMA-BF (28) (0.74%ID/g) at 2min after
injection. The uptake of 99mTc-BAT-BF (27)p e a k e da t
10min after injection, reaching 1.37%ID/g, suﬃcient uptake
for Aβ imaging, and 60% of the radioactivity had been
washed out from the brain by 60min after injection. The
uptake of 99mTc-MAMA-BF (28) peaked 30min after the
injection at 1.23%ID/g, and the washout from the brain
was slower than that of 99mTc-BAT-BF (27) throughout
the time course, which is unsuitable for imaging in vivo.
The combination of good aﬃnity for Aβ plaques, uptake,10 International Journal of Molecular Imaging
and clearance makes 99mTc-BAT-BF (27) a promising probe
for the detection of Aβ plaques in the brain. The results
of the present study should provide useful information for
the development of 99mTc-labeled probes for the imaging of
Aβ plaques in the brain, although there are some diﬃculties
associated with the large size of 99mTc complex in the
molecular design of 99mTc-labeled Aβ imaging probes to
enhance the penetration of blood-brain barrier.
4. Conclusion
Many PET probes targeting Aβ plaques in the brain have
been tested clinically and demonstrated potential utility.
Unfortunately, the short half-life (11C; 20min, 18F; 110min)
of 11C- or 18F-labeled probes except 18F-FDG limits their
use at major academic PET facilities with on-site cyclotrons
and sophisticated radiochemistry laboratories. On the other
hand, many more hospitals have the capacity to perform
SPECT. Aβ imaging probes labeled with SPECT isotopes
especially the inexpensive and readily available 99mTc will
have more widespread clinical applicability especially in
developing countries that cannot aﬀord expensive cyclotron
and PET scanners. The development of novel 123I- or 99mTc-
labeled Aβ imaging probes may lead to simple and conve-
nient SPECT imaging methods for detecting and eventually
quantifying Aβ plaques in living brain tissue.
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